Clinical trials: Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
This non-interventional study aims to observe the effect of early versus late Ofatumumab treatment in RMS patients in a real-world setting in Austria over an observational period of 24 months.
- Trial name
- KRONOS (NCT05776888)
- Testing
- Ofatumumab
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.
Relapse-remitting Multiple Sclerosis
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis
The purpose of this study is to study the effect of fingolimod on cardiac autonomic regulation in patients with relapse-remitting multiple sclerosis.
- Trial name
- FingoHRV (NCT01704183)
- Where
- 2 sites in Finland
- Volunteers
- 27 people
- Sponsor
- Kuopio University Hospital
Multiple Sclerosis
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical
This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed to assess the longitudinal pharmacokinetic, pharmacodynamic, immunological, and biochemical sample collection with MRI and relapse…
- Trial name
- NCT01330498
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- John F. Foley, MD
Multiple Sclerosis, Relapsing-Remitting
Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
The dimethyl fumarate is an oral drug, indicated in the treatment of the relapsing-remitting multiple sclerosis (MS) , which efficacy and safety has been assessed and validated in two randomised, placebo phase-controlled III…
- Trial name
- SURV-SEP (NCT02901106)
- Testing
- Dimethyl fumarate
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment…
- Trial name
- DELIVER-MS (NCT03535298)
- Testing
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Where
- 30 sites in United States, United Kingdom
- Volunteers
- 800 people
- Sponsor
- The Cleveland Clinic
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- SIZOMUS (NCT03783416)
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.
Relapsing Multiple Sclerosis (RMS)
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine…
- Trial name
- CHRONOS (NCT06486779)
- Testing
- Ofatumumab
- Where
- 15 sites in Greece
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Combination Therapy of Betaseron-Prograf in Multiple Sclerosis
The purpose of the study is to evaluate the safety and tolerability of a combination of interferon beta 1-b (Betaseron®) and tacrolimus (Prograf®) in patients suffering from multiple sclerosis (MS) who have failed treatment with…
- Trial name
- NCT00298662
- Testing
- Interferon beta-1b and Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
- Trial name
- NCT00030966
- Testing
- Natalizumab
- Where
- 88 sites in United States, Austria and 5 more
- Volunteers
- 1,200 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Treatment Interruption of Natalizumab
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
- Trial name
- RESTORE (NCT01071083)
- Testing
- natalizumab, interferon beta 1-a, methylprednisolone
- Where
- 33 sites in United States, Germany and 1 more
- Volunteers
- 175 people
- Sponsor
- Biogen
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
Multiple Sclerosis (MS) is a demyelinating auto immune disease of the central nervous system, affecting 2500000 people worldwide.
- Trial name
- CONFISEP (NCT05033782)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 1,209 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsing Remitting Multiple Sclerosis, Fatigue
Behavior Cognitive Therapy on Fatigue Impact in MS Patients
Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination of the central nervous system. Fatigue is one of the most frequent and most disabling symptoms of MS.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Cognitive Therapy
- Trial name
- NCT03758820
- Testing
- Behavorial Cognitive Therapy (BCT)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Réseau Sep Idf Ouest
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis
Little is known about the potential effects of exercise on the underlying disease mechanisms in multiple sclerosis (MS). Although contactin-1 and contactin-2 are known as two proteins involved in axonal regeneration, it is…
- Trial name
- NCT05351411
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Firat University
Multiple Sclerosis
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression…
- Trial name
- Cognition (NCT01333501)
- Testing
- Fingolimod, Interferon beta 1b
- Where
- 26 sites in Germany, Italy
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Views on Physical Activity Following a Relapse in People With Multiple Sclerosis
Multiple Sclerosis (MS) is the most common cause of neurological disability in young adults. Relapsing Remitting Multiple Sclerosis (RRMS) is the most frequent form of MS at the time of diagnosis characterised by relapses…
- Trial name
- NCT03736902
- Testing
- Qualitative semi structured interview
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- City, University of London